Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Cross

Showing results (271-280 of 313) with videos related to

Pageof 32
Sort By:
Alimentary Pharmacology & Therapeutics|July 26, 2024
Efficacy and safety of risankizumab by baseline corticosteroid use and achievement of corticosteroid-free clinical and endoscopic outcomes in patients with moderately to severely active Crohn's diseaseStefan Schreiber, Raymond K Cross, Remo Panaccione, et al.
British Journal of Cancer|November 26, 2009
A phase I study of the nitroimidazole hypoxia marker SR4554 using 19F magnetic resonance spectroscopyC P Lee, G S Payne, A Oregioni, et al.
Genome Research|January 18, 2013
Dynamic DNA methylation across diverse human cell lines and tissuesKatherine E Varley, Jason Gertz, Kevin M Bowling, et al.
Gastro Hep Advances|August 12, 2024
Multicenter Study of Nonadherence to Self-Injectable Biologic Therapy in Patients With Inflammatory Bowel Disease: Risk Factors and OutcomesLauren A George, Erin Causey, Nisha B Shah, et al.
The American Journal of Gastroenterology|June 25, 2025
A Prospective Comparison of Ustekinumab and Antitumor Necrosis Factor α Therapy in the Treatment of Crohn's-Like Disease of the PouchEdward L Barnes, Laura Raffals, Taha Qazi, et al.
Digestive Diseases and Sciences|January 4, 2019
Effect of TELEmedicine for Inflammatory Bowel Disease on Patient Activation and Self-EfficacyZaid Bilgrami, Ameer Abutaleb, Kenechukwu Chudy-Onwugaje, et al.
Digestive Diseases and Sciences|December 4, 2019
Correction to: Effect of TELEmedicine for Inflammatory Bowel Disease on Patient Activation and Self-EfficacyZaid Bilgrami, Ameer Abutaleb, Kenechukwu Chudy-Onwugaje, et al.
Inflammatory Bowel Diseases|May 23, 2018
Inflammatory Bowel Disease Telemedicine Clinical Trial: Impact of Educational Text Messages on Disease-Specific Knowledge Over 1 YearAmeer Abutaleb, Andrea Buchwald, Kenechukwu Chudy-Onwugaje, et al.
The American Journal of Gastroenterology|July 30, 2025
Inflammatory Bowel Diseases-Specific Cognitive Behavioral Therapy Delivered Through Telehealth Reduces Disability: Addressing Disability Effectively With Psychosocial Telemedicine Pragmatic Randomized Controlled TrialChung Sang Tse, James D Lewis, Sara N Horst, et al.
The American Journal of Gastroenterology|November 10, 2018
A Randomized Controlled Trial of TELEmedicine for Patients with Inflammatory Bowel Disease (TELE-IBD)Raymond K Cross, Patricia Langenberg, Miguel Regueiro, et al.
Pageof 32

Showing results (271-280 of 313) with videos related to

Sort By:
Pageof 32
Alimentary Pharmacology & Therapeutics|July 26, 2024
Efficacy and safety of risankizumab by baseline corticosteroid use and achievement of corticosteroid-free clinical and endoscopic outcomes in patients with moderately to severely active Crohn's diseaseStefan Schreiber, Raymond K Cross, Remo Panaccione, et al.
British Journal of Cancer|November 26, 2009
A phase I study of the nitroimidazole hypoxia marker SR4554 using 19F magnetic resonance spectroscopyC P Lee, G S Payne, A Oregioni, et al.
Genome Research|January 18, 2013
Dynamic DNA methylation across diverse human cell lines and tissuesKatherine E Varley, Jason Gertz, Kevin M Bowling, et al.
Gastro Hep Advances|August 12, 2024
Multicenter Study of Nonadherence to Self-Injectable Biologic Therapy in Patients With Inflammatory Bowel Disease: Risk Factors and OutcomesLauren A George, Erin Causey, Nisha B Shah, et al.
The American Journal of Gastroenterology|June 25, 2025
A Prospective Comparison of Ustekinumab and Antitumor Necrosis Factor α Therapy in the Treatment of Crohn's-Like Disease of the PouchEdward L Barnes, Laura Raffals, Taha Qazi, et al.
Digestive Diseases and Sciences|January 4, 2019
Effect of TELEmedicine for Inflammatory Bowel Disease on Patient Activation and Self-EfficacyZaid Bilgrami, Ameer Abutaleb, Kenechukwu Chudy-Onwugaje, et al.
Digestive Diseases and Sciences|December 4, 2019
Correction to: Effect of TELEmedicine for Inflammatory Bowel Disease on Patient Activation and Self-EfficacyZaid Bilgrami, Ameer Abutaleb, Kenechukwu Chudy-Onwugaje, et al.
Inflammatory Bowel Diseases|May 23, 2018
Inflammatory Bowel Disease Telemedicine Clinical Trial: Impact of Educational Text Messages on Disease-Specific Knowledge Over 1 YearAmeer Abutaleb, Andrea Buchwald, Kenechukwu Chudy-Onwugaje, et al.
The American Journal of Gastroenterology|July 30, 2025
Inflammatory Bowel Diseases-Specific Cognitive Behavioral Therapy Delivered Through Telehealth Reduces Disability: Addressing Disability Effectively With Psychosocial Telemedicine Pragmatic Randomized Controlled TrialChung Sang Tse, James D Lewis, Sara N Horst, et al.
The American Journal of Gastroenterology|November 10, 2018
A Randomized Controlled Trial of TELEmedicine for Patients with Inflammatory Bowel Disease (TELE-IBD)Raymond K Cross, Patricia Langenberg, Miguel Regueiro, et al.
Pageof 32